Navigation Links
ABACHEM: Reliable Development and Manufacturing Service Provider
Date:5/9/2013

SHANGHAI, May 9, 2013 /PRNewswire/ -- ABACHEM is a public listed company in China, specializing in contract manufacturing to the pharmaceutical, biotechnological and agrochemical industries. Offering a broad spectrum of services for the production of fine chemicals, advanced intermediates and active pharmaceutical ingredients, we have successfully collaborated and partnered with major pharmaceutical and agrochemical companies globally. ABACHEM has also become a reliable development and manufacturing service provider and meets clients' outsourcing needs by offering cost-effective and time-efficient services and products.

Our R&D department has over 80 scientists with solid industrial experience, providing process research and development services including process selection, optimization, and verification as well as reference standard and impurity preparations. Our laboratory is fully-equipped with modern analytical instruments such as NMR, HPLC, UPLC, LC-MS and GC-MS to ensure that all projects are delivered with accuracy and a high degree of purity. DSC and ARSST are applied to every project in our lab to provide a process safety and hazard assessment. Our four kilo-labs ensure that all kilo-projects are delivered on time. An isolated and state-of-the-art kilo-lab was recently built and dedicated to cGMP projects.

ABACHEM promotes innovation and is open-minded to new ideas and technologies. For example, we recognize that heterocyclic chemistry and asymmetric synthesis are the two most complex and intriguing branches of organic chemistry. The development of technologies and processes for heterocyclic and asymmetric synthesis have been areas of long-term focus for the company. Heterocycles manufactured based on processes developed in-house, such as pyrazoles, triazoles, aza-indoles and unnatural amino acids, are some of the highlights. For chiral technology, besides the traditional asymmetric synthesis, we have recently enhanced our capability by establishing a biocatalysis group.

ABACHEM has tremendous manufacturing capability and capacity. Five of our multi-functional pilot plants ensure a smooth tech-transfer from lab to commercial scale manufacturing. In addition, through years of CMO business, the company has accumulated invaluable knowledge and experience in bulk hazardous material sourcing and handling as well as regulatory filing including the latest New Chemicals Substance filing. We also have had a good track record of persistent improvement of cost structure for our clients' commercial products.

ABACHEM is continuously and actively improving its capabilities and capacity through new technologies & engineering as well as expansions for our core CMO services. We have recently expanded our hydrogenation capacity significantly by the installation of an additional eighteen hydrogenation reactors ranging from 1000 to 5000 L with two 1000L Hastelloy reactors to provide excellent material compatibility.

About ABACHEM

Founded in 2003, ABACHEM has developed into a public company with about 400 employees and over 1.2 million square feet of laboratory and manufacturing space. Currently, the company is headquartered in Shanghai with a R&D center in Zhangjiang Hi-Tech Park of Shanghai and three manufacturing facilities in Jiangsu province which are all within driving distance to Shanghai. 

Contact:

Jane Wang
janewang@abachem.com
+86-136-6184-2021


'/>"/>
SOURCE ABACHEM
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Defeat Diabetes Foundation Teams with CoreMedica Laboratories to Provide Affordable and Reliable A1C Testing for Diabetics
2. Varian Medical Systems to Showcase Fast, Reliable, Wireless X-ray Image Detectors at the ECR Annual Meeting in Vienna Next Week
3. Fuisz Pharma Announces Patent Allowance For New Tablet And Caplet Shapes That Promote Rapid, Reliable Esophageal Transit
4. JDRF and BD Collaborate to Develop More Accurate and Reliable Glucose Monitoring Devices for People with Type 1 Diabetes
5. Trevena, Inc. and Forest Laboratories Announce a Collaborative Agreement For Development of TRV027 for the Treatment of Acute Heart Failure
6. Tribogenics Expands X-Ray Development Team With Key Hires
7. FEEL Golf Co., Inc. Signs EMR Software Development Agreement with ScheduleMorePatients LLC
8. Regeneron Acquires Full Rights to Two Novel Ophthalmology Development Programs
9. Ambrx Initiates Collaboration with Bristol-Myers Squibb for Discovery, Development of Next-Generation Antibody Drug Conjugates
10. OncoGenex Pharmaceuticals, Inc. Provides Clinical Development Program Overview and Reports Financial Results for First Quarter 2013
11. Algeta and Lumiphore Announce Further Expansion of Their Global Partnership for the Development of Targeted Alpha-pharmaceutical Cancer Therapeutics and Companion Diagnostics.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2017)... 2017 Zymo Research Corp., also known as ,The Epigenetics Company, ... aging in a precise manner using the myDNAge ™ test. Based ... professor of human genetics and biostatistics at the David Geffen School ... , Zymo Research,s proprietary DNAge ™ technology is used to analyze ... ...
(Date:7/11/2017)... JERUSALEM , July 11, 2017 Oramed ... ), a clinical-stage pharmaceutical company focused on the development ... U.S. Food and Drug Administration (FDA) has agreed to ... successfully completed Phase IIb trial of its oral insulin ... The Phase IIb trial met primary and secondary endpoints ...
(Date:7/10/2017)... , July 10, 2017 Locus Biosciences ... Note to support the development of CRISPR-Cas3 antimicrobial therapeutics. ... Limited, a leading Chinese Internet services provider, and joined ... advance multiple infectious disease product programs targeting antibiotic resistant ... Founded by Dr. Rodolphe Barrangou ...
Breaking Medicine Technology:
(Date:7/26/2017)... San Jose, Calif (PRWEB) , ... July 26, 2017 , ... Six greater Bay Area ... save lives with “Make ‘em Bleed,” the most widely attended series of blood drives in ... 900 units of blood over the past 4 years -- enough to have helped to ...
(Date:7/26/2017)... ... ... It may be hard to imagine that the basic necessities that developed countries ... that many developed countries consider rare or eradicated, like measles, are still a rite ... an upcoming segment of "Success Files", actor Rob Lowe will introduce a new segment ...
(Date:7/26/2017)... ... July 27, 2017 , ... It's time to sign up for the ... great benefits," says Kathy Heshelow, founder of Sublime Naturals and author of numerous books on ... oil each month, mailed by the 5th. , Two items are included ...
(Date:7/26/2017)... ... ... “We are thrilled to be partnering with Six Month Smiles to work ... in real time,” said Keith English, LocalMed CEO. “Allowing patients the ability to schedule ... Month Smiles patients to their providers.” , Each month, over 25,000 patients research Six ...
(Date:7/26/2017)... ... 26, 2017 , ... Isodiol International Inc. (CSE: ISOL) (OTC: ... the development of pharmaceutical and consumer products, announces the operational numbers of its ... Iso International LLC recorded unaudited fiscal Q1 profits of $897,596 based on revenues ...
Breaking Medicine News(10 mins):